Vitamin D Deficiency in HIV-Infected Women on Antiretroviral Therapy Living in the Tropics

Journal of the International Association of Providers of AIDS Care (JIAPAC)

Volumn 10, Issue 4, 2011, Pages 239-245

  Conrado, Tereza ^a   de Barros Miranda Filho, Demócrito ^a   de Alencar Ximenes, Ricardo Arraes ^a,b   de Fátima Albuquerque, Maria ^c   Lacerda, Heloísa Ramos ^a,b   Ramos, Regina Coeli F ^a   de Araújo, Paulo Sérgio Ramos ^b   Montarroyos, Ulisses ^b   Bandeira, Francisco ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

antiretroviral therapy; HIV; vitamin D

Indexed keywords

VITAMIN D; ANTIRETROVIRUS AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLOOD; CROSS-SECTIONAL STUDY; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VITAMIN D DEFICIENCY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY MASS; BRAZIL; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TROPICS; VIROTHERAPY; VITAMIN D METABOLISM;

CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 80052826580     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109711399657     Document Type: Article

References (42)

1. UNAIDS, Aids Epidemic Update 2008. Internet: http://www.unaids.org.htm. Accessed May 15, 2009.
2. Ministério da Saúde. Boletim epidemiológico—Aids e DST. Brasília, DF: BR Government Printing Office, 2008. Internet: http://www.aids.gov.br.htm. Accessed May 15, 2009.
3. Villamor E. A potential role for vitamin D on HIV infection? Special article. Nutr Rev. 2006;64(5 pt 1):226–233.
4. Conrado T Miranda-Filho DB Bandeira F. Vitamin D deficiency in HIV-infected individuals: one more risk factor for bone loss and cardiovascular disease? Arq Bras Endocrinol Metab. 2010;54(2):119–123.
5. Van Den Bout-Van Den Beukel CJP Fievez L Michels M. Vitamin D deficiency among HIVtype 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24(11):1–8.
6. Stephensen CB Marquis GS Kruzich LA Douglas SD Aldrovandi GM Wilson CM. Vitamin D status in adolescentes and young adults with HIV infection. Am J Clin Nutr. 2006;83(5):1135–1141.
7. Haug CJ Aukrust P Haug E. Deficiency1,25didroxi vitamin D3 in human immunodeficiency hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metabolica. 1998;83:3832–3838.
8. Cozzolino M Vidal M Arcidiacono MV Tebas P Yarasheski KE Dusso AS. HIV protease inhibitor impair vitamin D bioactivation 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–520.
9. Holick MF. Mayo Clinic Review.High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–373.
10. Holick M. F. Vitamin D deficiency-review article. New Eng J Med. 2007;357(3):266–281.
11. Wang TJ Pencina MJ Booth SL. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.
12. Melamed ML Michos ED Post W. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–1637.
13. Giovannucci E Liu Y Hollis BW Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men. A prospective study. Arch Intern Med. 2008;168(11):1174–1180.
14. Kremer R Campbell PP Reinhard T Gilsanz V. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab. 2009;94(1):67–73.
15. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;1(suppl 1):S141–S148.
16. Grinspoon S Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.
17. Signorini DJHP Monteiro MCM Signorini DH Eyer-Silva WA Arq Bras Endocrinol Metab. 2010;54:583.
18. Friis-Møller N Reiss P DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
19. Yin M Dobkin J Brudney K. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporosis Int. 2005;16(11):1345–1352.
20. Madeddu G Spanu A Solinas P. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39–48.
21. Bandeira F Griz L Dreyer P Bandeira C Eufrazino C Freese E. Vitamin D deficiency: a global perspective. Arq Bras Endocrinologia Metab. 2006;50(4):640–645.
22. Friedewald WT Levy R FredricksonD S. Estimation of the concentration pf low lipoprotein cholesterol in plasma without us of the preparative ultracentrifuge. Clin Chem. 1972;18:499–504.
23. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(6 suppl):S1706–S1709.
24. Chobanian AV Bakris GL Black HR and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
25. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Grundy SM Cleeman JI Daniels SR. Circulation. 2005;112(17):2735–2752.
26. Grundy SM Brewer HB Cleeman JI Smith SC Jr Lenfant C. The American Heart Association, the National Heart, Lung, and Blood Institute: definition of metabolic syndrome: report of. Circulation. 2005;112(3):285–290.
27. Alberti KGMM Zimmet P Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diab Med. 2006;23(5):469–480.
28. Geloneze B Repetto EM Geloneze SR. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study (BRAMS). Diabetes Res Clin Pract. 2006;72(2):219–220.
29. Wilson PW D'Agostino RB Levy D Belanger AM Silbershatz H Kannel WB. Prediction of coronary heart disease using risk factor categories (FRAMINGHAM). Circulation. 1998;97(18):1837–1847.
30. Assmann G Cullen P Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM). Circulation. 2002;105( ):310–315.
31. CDC: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR. 1992;41(RR-17):1–19.
32. Gelenske T Farias FAB Ximenes RAA. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: case-control study. Metabolic Syndrome Related Disorders. 2010;8(3):271–277.
33. Craig CL Marshall A Sjostrom M. International physical activity questionnaire: 12 country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–1395.
34. Martelli CMT Turchi MD Souto FJD Sáez-Alquézar A Andrade ALSS Zicker F. Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity. Rev Panam Salud Pública. 1999;6(1):69–73.
35. Dawson-Hughes B Harris SS Rasmussen H Song L Dallal GE. Effect of dietary protein supplements on calcium excretion in healthy older men and women. J Clin Endocrinol Metab. 2004;89(3):1169–1173.
36. Dourado I Veras MASM Barreira D Brito AM. Tendências da epidemia de Aids no Brasil após a terapia anti-retroviral. Rev Saúde Pública. 2006;40(suppl):9–17.
37. Pernerstorfer-Schoen H Jilma B Perschler A. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001;15(6):725–734.
38. Rodríguez M Daniels B Gunawardene S Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14.
39. Looker AC Dawson-Hughes B Calvo S Gunter EW Sahyoun NR. Serum 25-Hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30(5):771–777.
40. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV infected patients. J Acquir Immune Defic Syndr. 2008;49(suppl):S79–S85.
41. Sankatsing RR Franssen R Hassink E. Nevirapine increases high density lipoprotein-cholesterol by stimulation of apoprotein A1 synthesis. Antiviral Ther. 2007;12(suppl):S2–S5.
42. Liang JS Distler O Cooper DA. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7(12):1327–1331.